Axial spondylarthritis following COVID-19 infection

Published Date: 25th May 2023

Publication Authors: Gopalarathinam R, Nawimana S, Nune A

Although SARS-CoV-2 syndrome primarily affects the lungs, systemic manifestations have been reported. New rheumatic immune-mediated inflammatory diseases have been reported following SARS-CoV-2 infection. We present a case of a woman in her mid-30s who developed inflammatory back pain due to bilateral sacroiliitis with erosions after contracting SARS-CoV-2 infection. Her inflammatory markers on presentation were normal. MRI of the sacroiliac joints demonstrated bone marrow oedema and erosive changes in both sacroiliac joints. As the patient was intolerant to non-steroidal anti-inflammatory drugs, adalimumab 40 mg subcutaneous (SC) injection was administered, which improved her symptoms in 8 weeks. However, due to the drug’s side effects, SC adalimumab was switched to intravenous infliximab. The patient is currently tolerating her intravenous infliximab well and has experienced significant improvement in her symptoms. We reviewed the current literature on the prevalence of axial spondyloarthropathy after SARS-CoV-2 infection.

Gopalarathinam, R.; Nawimana, S.; Nune, A. (2023). Axial spondylarthritis following COVID-19 infection. BMJ Case Reports. 16(5), p.-. [Online]. Available at: https://doi.org/10.1136/bcr-2022-252985 [Accessed 27 February 2024].

« Back